– USA, MA –  Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Graham Cooper to its board of directors.

“Graham brings significant experience leading biotech companies through rapid growth, and we are thrilled to welcome him to our board of directors,” said John Evans, CEO Beam Therapeutics. “As we continue to grow and progress our lead programs toward clinical development, his expertise in financial operations and capital markets strategy will be invaluable.”

About Graham Cooper

Mr. Cooper was previously the chief financial officer and chief operating officer of Assembly Biosciences, a biotechnology company developing innovative therapeutics targeting hepatitis B virus. Prior to joining Assembly, he was CFO of Receptos, from 2013 until its sale in 2015 to Celgene. Previously, Mr. Cooper was the CFO of Geron Corporation, and from 2006 until 2011, served as CFO of Orexigen Therapeutics. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including director of healthcare investment banking at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From 1992 to 1995, he worked as an accountant at Deloitte & Touche, where he earned his C.P.A. Mr. Cooper is a member of the boards of directors of other public companies including Unity Biotechnology and Kezar Life Sciences.

“Beam’s unique base editing approach has the potential to transform the way many diseases are treated today,” said Mr. Cooper. “I am inspired by the team and the science at Beam and the opportunity to create important new treatment options for patients. I look forward to working with the team and helping to guide them through their next phase of development.”

Mr. Cooper holds a B.A. in economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.

About Beam Therapeutics

Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts.

For more information: https://beamtx.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.